Advertisement
Canada markets closed
  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.19 (+0.34%)
     
  • CAD/USD

    0.7350
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    79.88
    -0.18 (-0.22%)
     
  • Bitcoin CAD

    90,110.54
    -1,023.52 (-1.12%)
     
  • CMC Crypto 200

    1,354.40
    -19.44 (-1.41%)
     
  • GOLD FUTURES

    2,422.90
    +5.50 (+0.23%)
     
  • RUSSELL 2000

    2,095.72
    -0.53 (-0.03%)
     
  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     
  • NASDAQ futures

    18,658.75
    +23.50 (+0.13%)
     
  • VOLATILITY

    11.99
    -0.43 (-3.46%)
     
  • FTSE

    8,420.26
    -18.39 (-0.22%)
     
  • NIKKEI 225

    38,787.38
    -132.92 (-0.34%)
     
  • CAD/EUR

    0.6757
    +0.0002 (+0.03%)
     

Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations

Entrada Therapeutics (NASDAQ:TRDA) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$59.1m (up 134% from 1Q 2023).

  • Net income: US$23.5m (up from US$6.67m loss in 1Q 2023).

  • Profit margin: 40% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.

  • EPS: US$0.70 (up from US$0.21 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Entrada Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 4.8% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Entrada Therapeutics' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.